

Drug Delivery in Cancer

Part I: Technologies & Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 473 publications include 28 books (5 as editor+ 23 as author) and 50 commercial reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

Edited books include "Drug Delivery Systems" (1st ed Humana/Springer 2008; 2nd ed 2014) and "Drug Delivery to the Central Nervous System" (Humana/Springer, 2010). As an author, his recent books include "Handbook of Nanomedicine" (Springer/Humana 2008; Chinese edition, Peking University Press 2011; 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical industry Press 2016, 2nd ed Springer 2017), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer, 2014). He has edited "Applied Neurogenomics" (Springer 2015).

A B O U T T H I S R E P O R T

The original report on Drug Delivery in Cancer by the author was published by Decision Resources Inc in 2000 as an enlargement of the chapter on this topic in his report on Drug Delivery Technologies (1998), which was also published by Decision Resources. The second edition was published at Jain PharmaBiotech in 2003 and has been constantly updated and rewritten since then.

**November 2017 (first edition published in 2000)
Copyright © 2017 by**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	19
1. Introduction to cancer therapy	21
Molecular biology of cancer	21
Cell cycle and cancer	21
<i>Apoptosis in cancer</i>	22
<i>Autophagy</i>	22
<i>Cell division and mitotic spindles</i>	23
<i>PD-1 Pathway</i>	23
<i>DNA damage, repair and cancer</i>	24
<i>Mechanism of DNA damage in Fanconi anemia leading to leukemia</i>	24
Cancer metabolism and energy status in relation to growth	24
<i>Amino acids and cancer</i>	24
<i>AMP-activated protein kinase</i>	25
<i>Cancer therapeutics that target metabolism</i>	25
Cancer cell dormancy	26
<i>Dormancy and relapse in cancer</i>	26
<i>Activating dormant cancer cells for enhancing chemotherapy</i>	26
Chromosomes and cancer	27
<i>Aneuploidy</i>	27
<i>Chromosomal instability</i>	27
<i>Telomeres and cancer</i>	28
Genes and cancer	28
<i>Accumulation of random mutations</i>	29
<i>Oncogenes</i>	29
<i>Role of Bub 1 gene in cell division</i>	29
<i>Tumor Suppressor Genes</i>	30
Hallmarks of cancer	31
Invasion and metastases	31
<i>Tumor suppressor genes and metastases</i>	32
Methylation and cancer	33
Oxidative stress and cancer	33
Role of platelet-derived growth factor in proliferation of cancer	33
RNA and cancer	34
<i>Anticancer treatments based on RNA regulation of genes</i>	34
<i>Role of microRNAs in cancer</i>	34
Stem cells and cancer	35
Self-sufficiency of tumor proliferation	35
Therapeutic implications of apoptosis in cancer	36
Tumor angiogenesis	37
<i>Pathomechanism of angiogenesis</i>	38
<i>Role of VEGF in angiogenesis</i>	39
<i>Matrix stiffness-mediated angiogenesis in tumors</i>	39
Cancer biomarkers	40
Molecular imaging of cancer	40
Cancer genomics	40
Gene expression profiling in cancer	41
Cancer proteomics	41
Limitations of genomics and proteomics for understanding cancer	41
Cancer microenvironment	42
Epidemiology of cancer	42
Current management of cancer	43
Anticancer drugs	43
<i>Limitations of cancer chemotherapy</i>	44
Biological therapies for cancer	44
Radiotherapy	44
<i>Brachytherapy</i>	44
Ideal anticancer agent	45
Surgery	45
Basics of drug delivery in cancer	45
Role of mechanical forces in tumor growth and delivery of therapy	46
Methods of assessing drug delivery in cancer	46
Positron emission tomography (PET)	46
Historical landmarks in cancer drug delivery	46
2. Innovative treatments for cancer	49
Introduction	49

Selective estrogen receptor modulators	50
Antiangiogenic strategies for cancer	51
Development of antiangiogenic therapies	51
Classification of antiangiogenic agents	52
Examples of antiangiogenic agents	53
<i>ACE-041</i>	53
<i>Angiopoietin-2 as a target</i>	53
<i>Chemotherapy at lower than maximum tolerated dose</i>	53
<i>Galectin-3 as a target for inhibiting angiogenesis</i>	54
<i>Inhibitors of endothelial proliferation</i>	54
<i>Inducers of apoptosis of endothelial cells of tumor vessels</i>	54
<i>Lodamin</i>	55
<i>Matrix metalloproteinase inhibitors</i>	55
<i>Monoclonal antibodies with vasculostatic properties</i>	56
<i>PPARα agonists</i>	57
<i>Rapalogues as antiangiogenic agents</i>	57
<i>VEGF Trap</i>	58
Agents that decrease the permeability of tumor blood vessels	58
Antiangiogenic agents in clinical trials	58
Antiangiogenic therapy resistance	59
Combination of antiangiogenic with cytotoxic therapy	59
Antiangiogenic therapy for hematological malignancies	59
Bacterial anticancer agents	60
Tumor-targeted bacteria	61
<i>Bacterial protein for targeted delivery of liposomal cancer drugs</i>	61
<i>Genetically modified bacteria as anticancer agents</i>	61
<i>Live bacteria for delivering radioactive anticancer agents</i>	62
<i>Synchronized cycles of bacterial lysis with delivery of chemotherapy</i>	63
<i>Genetically altered strains of Salmonella as anticancer drug vectors</i>	63
Inactivated but metabolically active bacteria	64
Bacterial toxins targeted to tumors	64
<i>Immunotoxins</i>	64
<i>Escherichia Coli toxins</i>	64
<i>Engineered anthrax toxin</i>	65
<i>Recombinant fusion toxins</i>	65
Type III secretion systems	67
Induction of apoptosis in cancer by bacterial proteins	67
Induction of immune response by bacteriolytic therapy	67
Epigenetic targets for anticancer therapy	68
Innovations in cell therapy for cancer	68
Stem cell transplantation for cancer	69
Cancer drug/gene delivery by mesenchymal stem cells	69
Cancer immunotherapy	70
Cytokines	70
Epigenetic modulators and cancer immunotherapies	71
STING activation and antitumor immunity	73
Cancer vaccines	73
<i>5T4 as a target for cancer immunotherapy</i>	74
<i>Adoptive cell therapy</i>	74
<i>Antigen-specific cancer vaccines</i>	77
<i>Carcinoembryonic antigen-based vaccines</i>	78
<i>Carbohydrate-based cancer vaccines</i>	78
<i>Dendritic cells for cancer vaccination</i>	78
<i>Hybrid cell vaccination</i>	80
<i>SMART vaccines</i>	81
<i>Salmonella-based oral vaccine delivery</i>	81
<i>Tumor cell vaccines</i>	81
<i>Vaccines that simultaneously target different cancer antigens</i>	82
<i>Vaccines based on multiple tumor-associated peptides</i>	82
<i>Vaccine for cancer based on antimalaria protein</i>	83
Cancer Vaccine Consortium	83
Chemoimmunotherapy	83
Concluding remarks about cancer vaccines	84
Targeted delivery of peptides to tumor-associated macrophages	84
Targeting cancer stem cells	84
Monoclonal antibodies	85
Murine MAbs	85
Humanized MAbs	85
Actions and uses of MAbs in cancer	86
Targeted antibody-based cancer therapy	87
<i>Antibody-cytokine fusion proteins</i>	87

<i>Antibody ARGX-115 for targeting immunosuppressive effect of Tregs</i>	87
<i>Antibody J591 for targeted delivery of anticancer therapy</i>	87
<i>Anti-Thomsen-Friedenreich antigen MAb</i>	87
<i>Combining MAbs with anti-CD55 antibody</i>	88
<i>MAbs targeted to alpha fetaprotein receptor</i>	88
<i>MAbs that target angiogenesis</i>	88
MAbs for immune activation	89
Delivery of cancer therapy with MAbs	89
Antibody-directed enzyme prodrug therapy	90
Chemically programmed antibodies	90
Combining diagnostics with therapeutics based on MAbs	91
Radiolabeled antibodies for detection and targeted therapy of cancer	91
Other innovations for administration of antibodies	94
<i>Bispecific antibodies</i>	94
<i>Trifunctional antibodies</i>	95
<i>Tetravalent bispecific antibodies</i>	95
<i>Immunotoxins</i>	95
<i>Immunoliposomes</i>	96
<i>Combined use of MAbs and cytokines</i>	96
<i>huHMFG1-huDNase I</i>	97
<i>MAbs that selectively target cancer</i>	97
NanoMAbs for targeting cancer	97
Advantages and limitations of MAbs for cancer therapy	98
Antibody-drug conjugates	99
<i>Kadcyla</i>	100
<i>Adcetris</i>	100
Antibody-enzyme conjugates	101
Current and future trends in antibody-based cancer drugs	101
Innovative methods of radiation delivery	101
Image-guided ultrasound technology for delivery of radiation	101
Respiratory gating technology for radiation therapy	101
Positron therapy	102
Boron neutron capture therapy	102
<i>Application of drug delivery systems to BNCP</i>	103
<i>Use of nanotechnology to enhance BNCT</i>	104
Ion channels and transporters in cancer	104
Irreversible electroporation	105
Methods to overcome multidrug resistance (MDR)	105
Mechanism of MDR	105
<i>MDR-associated protein gene</i>	106
<i>P-glycoprotein-mediated MDR</i>	106
Strategies for overcoming MDR	106
<i>Blocking the action of P-glycoprotein</i>	106
<i>Combination of targeted drugs with different specificities</i>	107
<i>Enzyme Catalyzed Therapeutic Activation</i>	107
<i>Inhibition of DNA repair</i>	107
<i>Iron chelators that overcomes resistance to chemotherapeutics</i>	108
<i>Liposome formulation of anticancer drugs</i>	108
<i>Modification of the chemical structure of the anticancer drug</i>	109
<i>Managing resistance to antiapoptotic action of anticancer agents</i>	109
<i>Modulation of SPARC expression</i>	109
<i>Nitric oxide inducers</i>	109
<i>Proton pump inhibitors</i>	110
<i>Repression of Prohibitin1 in drug-resistant cancer cells</i>	110
Targeted cancer therapies	110
Targeting cellular pathways	110
Targeting antigens in virus-associated cancer	111
Targeting the IGF-I receptor	111
Targeting Mcl-1 protein	112
Targeting mitochondrial membranes	112
Targeting tumor lymphatics	113
<i>LyP-1 for targeting tumor lymphatics</i>	113
Targeting tyrosine kinase receptors	114
<i>Inhibitors of bcr-abl tyrosine kinase</i>	114
<i>Inhibition of multiple tyrosine kinases</i>	114
<i>Inhibitors of ErbB tyrosine kinase</i>	114
Targeting the Hedgehog signaling pathway	115
Targeting caspase-8	116
Targeting metallodrugs to tumor cells	116
Targeting oncogenes	116
Targeting miRNA for cancer therapeutics	117

Targeting the transferrin receptor-mediated endocytosis pathway	117
Targeted anticancer therapies based on the Rad51 promoter.....	118
Targeting cancer stem cells	118
Targeting glycolytic pathway in cancer.....	119
Targeting glycoproteins	120
<i>Tagging cancer with modified sugars</i>	120
<i>Anticancer agents based on glycobiology</i>	120
<i>Targeting cell surface glycoproteins</i>	120
<i>Biofusion for targeted cancer therapy</i>	121
Targeting knottin peptides	121
Tarveda's Pentarin platform for targeted drug conjugates	122
Enhancing the effects of radiation and chemotherapy	122
Sensitizing and enhancing agents for chemotherapy.....	122
<i>CoFactor to enhance the efficacy of chemotherapy</i>	122
<i>Enzyme-enhanced chemotherapy</i>	123
<i>Resveratrol and quercetin for cardioprotection against chemotherapy</i>	123
<i>Tesmilifene for chemosensitization</i>	123
Sensitizing agents for radiotherapy	124
<i>IPdR</i>	124
<i>Ultrasound for enhancing response to radiation</i>	124
Manipulation of tumor oxygenation	125
<i>Hypoxia-based methods to enhance chemotherapy and radiotherapy</i>	125
<i>Hyperbaric oxygen and radiation</i>	126
<i>HIF-1 antagonists to enhance radiotherapy</i>	126
<i>Nonsteroidal antiinflammatory drugs enhance tumor radiosensitivity</i>	126
<i>ONCONASE as radiosensitivity enhancer</i>	126
Hyperthermia and chemotherapy/radiation therapy.....	127
<i>Techniques for hyperthermia</i>	127
<i>Trimodality therapy: radiation, chemotherapy, and hyperthermia</i>	127
Photodynamic therapy	128
<i>Photochemical internalization</i>	130
Thermal combination with focused ultrasound for drug delivery to tumors.....	130
Novel anticancer agents	131
Anti-EphA2 antibodies	131
Antioxidants	131
Brostallicin	131
Agents disrupting folate metabolism.....	132
<i>Pemetrexed</i>	132
Cell cycle inhibitors	132
Cytotoxic ribonucleases	133
DNA hypomethylating agents	133
Histone-based cancer therapy	133
<i>Histone deacetylase inhibitors</i>	134
<i>Modulation of p300/CBP histone acetyltransferase activity</i>	134
<i>Simulation of endogenous histone for anticancer therapy</i>	135
HSP90 inhibitors	135
Ion channel blockers	136
<i>IOT-101</i>	136
<i>Endovion</i>	136
LPAAT- β inhibitors.....	136
Modulation of pyruvate kinase M2	137
Modulators of protein ubiquitination	137
P13-kinase inhibitors.....	137
PARP inhibitors	137
<i>Targeted destruction of BRCA2 deficient tumors by PARP inhibitors</i>	138
<i>Companies developing and commercializing PARP inhibitors</i>	138
Prodrugs.....	139
<i>Enzyme-activated prodrugs</i>	139
<i>Ascorbic acid as a prodrug for cancer</i>	139
<i>Prolarix</i>	140
Procaspase-3 activation	140
Protein kinase G activation.....	140
Proteasome inhibitors	141
Recombinant human insulin-like growth factor binding protein-3.....	141
Second generation nucleosides	141
Targeting cancer metabolism.....	142
Targeting topoisomerase IB	142
Telomerase inhibitors	143
Therapeutic strategies based on the P53 pathway	143
Therapeutic strategies based on molecular mechanisms.....	144
<i>Checkpoint activation as a strategy against cancer</i>	144

<i>Deletion-specific targeting for cancer therapy</i>	145
<i>In vivo models for molecularly anticancer drugs</i>	145
<i>Repair-blocking drugs for enhancing effect of chemotherapy</i>	145
<i>Tumor targeting fields</i>	146
<i>Targeting mTOR signaling defects</i>	146
Combining novel anticancer approaches.....	146
Personalized therapy of cancer	147
Challenges of cancer classification.....	150
Design of future cancer therapies.....	150
Personalized drug development in oncology	151
<i>Role of molecular imaging</i>	151
<i>Role of molecular imaging in targeted cancer therapy</i>	152
<i>Screening for personalized anticancer drugs</i>	152
<i>Targeting pathways for personalized cancer therapy</i>	152
3. Drug delivery systems for cancer	154
Introduction	154
Routes of drug delivery in cancer	154
Intravenous delivery systems for cancer therapy	155
<i>Intravenous versus oral ascorbate for treatment of cancer</i>	156
Subcutaneous injection of anticancer agents	156
Oral delivery of anticancer agents	156
<i>5-FU combined with eniluracil</i>	158
<i>Cyclin D-dependent CDK4 and CDK6 inhibitors</i>	158
<i>High dose administration of calcitriol</i>	158
<i>Oral fluoropyrimidines</i>	159
<i>Oral gefitinib vs intravenous docetaxel</i>	159
<i>Oral paclitaxel</i>	160
<i>Oral satraplatin</i>	160
<i>Oral UFT</i>	160
<i>Oral PXD101</i>	161
Transdermal drug delivery	161
<i>Delivery of the photosensitizer drug δ-amino levulinic acid</i>	161
<i>Nanoemulsion-based delivery of caffeine for skin cancer</i>	161
<i>Transdermal delivery of methotrexate</i>	162
<i>Transdermal nitroglycerine for prostate cancer</i>	162
<i>Transdermal delivery of peptide cancer vaccines</i>	162
<i>Intradermal delivery of cancer vaccines by adenoviral vectors</i>	162
Pulmonary delivery of anticancer agents	163
Regional intra-arterial delivery of chemotherapy	163
Gas embolotherapy of tumors.....	164
Drug delivery to lymph nodes.....	164
Intraperitoneal macrophages as drug delivery vehicle.....	165
Challenges of cancer drug delivery	165
Tumor blood vessel pore barrier to drug delivery	165
Improvement of drug transport in tumors	165
Delivery of anticancer drugs to nuclear targets	166
Innovative formulations for drug delivery in cancer	167
Cancer targeting with polymeric drugs.....	167
<i>Linking anticancer drugs to polyglutamate</i>	168
<i>Improving delivery of protein-polymer anticancer drugs</i>	168
Macromolecules as delivery systems for taxanes.....	169
Polyamine conjugates as anticancer agents	169
Bacterial vectors as drug delivery systems for anticancer drugs	169
Microparticles as therapeutic delivery systems in cancer	170
<i>Subcutaneous injection of microspheres carrying anticancer drugs</i>	170
<i>Intravascular delivery systems using microparticles</i>	171
<i>Tumor embolization with drug-eluting beads</i>	171
<i>Tumor embolization with radioactive microparticles</i>	171
<i>Microparticles heated by magnetic field</i>	172
<i>Magnetic targeted microparticle technology</i>	172
<i>Release of drugs from biSphere by ultrasound</i>	172
<i>Release of drugs from micelles by ultrasound</i>	173
<i>Release of drugs from microcapsules by laser</i>	173
<i>Chemoembolization</i>	174
<i>Anticancer drugs bound to carbon particles</i>	174
<i>Anticancer drugs bound to protein microspheres</i>	174
<i>Nanoerythroosomes</i>	174
<i>Micronized droplets of olive oil</i>	174
Nanobiotechnology-based drug delivery for cancer	175
Nanoparticle formulations for drug delivery in cancer	176

<i>Anticancer drug particles incorporated in liposomes</i>	176
<i>Doxorubicin nanocarriers</i>	178
<i>Encapsulating drugs in hydrogel nanoparticles</i>	179
<i>Exosomes</i>	179
<i>Folate-linked nanoparticles</i>	180
<i>Lipid based nanocarriers</i>	180
<i>Micelles for drug delivery in cancer</i>	180
<i>Minicells for targeted delivery of nanoscale anticancer therapeutics</i>	182
<i>Nanobombs for cancer</i>	182
<i>Nanodiamonds for local delivery of chemotherapy at site of cancer</i>	183
<i>Nanoparticle formulation for enhancing anticancer efficacy of cisplatin</i>	183
<i>Nanoparticle formulations of paclitaxel</i>	184
<i>Nanoparticles containing albumin and antisense oligonucleotides</i>	184
<i>Nanotechnology-based non-invasive refilling of drug delivery depots</i>	184
<i>Non-aggregating nanoparticles</i>	185
<i>Pegylated nanoliposomal formulation</i>	185
<i>Perfluorocarbon nanoparticles</i>	185
<i>Protein nanocages for penetration of airway mucous and tumors</i>	185
<i>Protosphere nanoparticle technology</i>	186
Nanoparticles-based targeted delivery of therapeutics for cancer	186
<i>Antiangiogenic therapy using nanoparticles</i>	187
<i>Carbon magnetic nanoparticles for targeted drug delivery in cancer</i>	188
<i>Carbon nanotubes for targeted drug delivery to cancer cells</i>	188
<i>CRLX101 for targeted anticancer drug delivery</i>	189
<i>DNA aptamer-micelle for targeted drug delivery in cancer</i>	189
<i>Fullerenes for enhancing tumor targeting by antibodies</i>	189
<i>Gold nanoparticles for targeted drug delivery in cancer</i>	190
<i>Hepatic artery infusion of LDL-DHA nanoparticles for liver cancer</i>	191
<i>Iron oxide magnetic nanoparticle formulation for drug delivery</i>	191
<i>Lipoprotein nanoparticles targeted to cancer-associated receptors</i>	191
<i>Magnetic nanoparticles for remote-controlled drug delivery to tumors</i>	192
<i>Monitoring of targeted delivery by nanoparticle-peptide conjugates</i>	193
<i>Nanobees for targeted delivery of cytolytic peptide melittin</i>	193
<i>Nanocell for targeted drug delivery to tumor</i>	193
<i>Nanodroplets for site-specific cancer treatment</i>	194
<i>Nanogel-based stealth cancer vaccine targeting macrophages</i>	194
<i>Nanoparticle-mediated targeted delivery of peptides into tumors</i>	195
<i>Nanoparticle-mediated targeting of MAPK signaling pathway</i>	195
<i>Nanoparticles for targeted delivery of concurrent chemoradiation</i>	196
<i>Nanostructured hyaluronic acid for targeted drug delivery in cancer</i>	196
<i>Nanoparticles as antibody-drug conjugates</i>	196
<i>Nanoparticle-coated peptides for tumor targeting</i>	196
<i>Nanoparticle-mediated delivery of multiple anticancer agents</i>	197
<i>Polymer nanoparticles for targeted drug delivery in cancer</i>	197
<i>Polymersomes for targeted cancer drug delivery</i>	197
<i>Targeted drug delivery with nanoparticle-aptamer bioconjugates</i>	198
<i>Targeted nanoparticles delivery of cisplatin to mitochondrial genome</i>	199
<i>Time-delayed, dual-drug nanoparticle delivery system for cancer</i>	199
Dendrimers for anticancer drug delivery	200
<i>Application of dendrimers in boron neutron capture therapy</i>	200
<i>Application of dendrimers in photodynamic therapy</i>	201
<i>Dendrimer-based synthetic vector for targeted cancer gene therapy</i>	202
Devices for nanotechnology-based cancer therapy	202
<i>Convection-enhanced delivery with nanoliposomal CPT-11</i>	202
<i>Nanocomposite devices</i>	202
<i>Nanoengineered silicon for brachytherapy</i>	203
<i>Nanosensors for targeted drug delivery in cancer</i>	203
Nanoparticles combined with physical agents for tumor ablation	203
<i>Carbon nanotubes for laser-induced cancer destruction</i>	203
<i>Nanoparticles and thermal ablation</i>	204
<i>Nanoparticles combined with ultrasound radiation of tumors</i>	206
<i>Nanoparticles as adjuncts to photodynamic therapy of cancer</i>	206
<i>Nanoparticles for boron neutron capture therapy</i>	207
RNA nanotechnology for delivery of cancer therapeutics	207
Nanocarriers for simultaneous delivery of multiple anticancer agents.....	208
Combination delivery systems for nanoparticle penetration into tumor tissue	208
Combination of diagnostics and therapeutics for cancer	209
<i>Biomimetic nanoparticles targeted to tumors</i>	209
<i>Dendrimer nanoparticles for targeting and imaging tumors</i>	209
<i>Gold nanoparticle plus bombesin for imaging and therapy of cancer</i>	209
<i>Gold nanorods for diagnosis plus photothermal therapy of cancer</i>	209

<i>Magnetic nanoparticles for imaging as well as therapy of cancer</i>	210
<i>Nanobialys for combining MRI with delivery of anticancer agents</i>	210
<i>pHLIP nanotechnology for detection and targeted therapy of cancer</i>	211
<i>Polymer nanobubbles for targeted and controlled drug delivery</i>	211
<i>Radiolabeled carbon nanotubes for tumor imaging and targeting</i>	211
<i>Targeted therapy with magnetic nanomaterials guided by antibodies</i>	212
<i>Ultrasonic tumor imaging and targeted chemotherapy by nanobubbles</i>	212
<i>Future prospects of nanobiotechnology and targeted cancer therapy</i>	212
Polyethylene glycol technology	213
Enzon's PEG technology	213
Debiopharm's PEG biconjugate drug delivery platform	213
Nektar PEGylation	214
PEG Intron	214
Single-chain antibody-binding protein technology	214
Vesicular systems for drug delivery in cancer	215
Liposomes for anticancer drug delivery	215
Antibody-targeted liposomes for cancer therapy	216
ALZA's Stealth liposomes	216
Boron-containing liposomes	217
DepoFoam technology	217
Hyperthermia and liposomal drug delivery	217
Liposomal doxorubicin formulation with N-octanoyl-glucosylceramide	218
Liposome-nucleic acid complexes for anticancer drug delivery	218
Non-pegilated liposomal doxorubicin	218
Tumor-selective targeted drug delivery via folate-PEG liposomes	218
Ultrasound-mediated anticancer drug release from liposomes.....	219
Companies developing liposome-based anticancer drugs.....	219
Pharmacosomes for controlled anticancer drug delivery	220
Emulsion formulations of anticancer drugs	221
Albumin-based drug carriers	221
Anticancer drugs that bind to tumors	221
Monoclonal T cell receptor technology	221
Radioactive materials for diagnosis and targeted therapy of cancer	222
Peptide receptor radionuclide therapy	222
Pretargeted radioimmunotherapy of cancer	222
Radiolabeled somatostatin receptor antagonists.....	223
Theophylline enhances radioiodide uptake by cancer	223
Strategies for drug delivery in cancer	223
Direct introduction of anticancer drugs into the tumor	224
<i>Injection into the tumor</i>	224
<i>Antineoplastic drug implants into tumors</i>	225
<i>Tumor necrosis therapy</i>	226
<i>Injection into the arterial blood supply of cancer</i>	226
<i>Electrochemotherapy</i>	228
<i>Pressure-induced filtration of drugs across vessels to the tumor</i>	228
Improving drug transport to tumors	228
<i>Carbohydrate-enhanced chemotherapy</i>	228
<i>Dextrans as macromolecular anticancer drug carriers</i>	229
<i>In situ production of anticancer agents in tumors</i>	229
<i>Iotophoresis for localized delivery of cancer chemotherapy</i>	229
Strategies for increasing drug penetration into solid cancers	230
Selective destruction of cancer cells	230
<i>Hyperbaric oxygen</i>	230
<i>Sphingolipids</i>	231
<i>Targeting response to transformation-induced oxidative stress</i>	231
<i>Targeting enzymes to prevent proliferation of cancer cells</i>	231
Targeted drug delivery in cancer.....	231
<i>Affibody molecules for targeted anticancer therapy</i>	232
<i>Fatty acids as targeting vectors</i>	232
<i>Genetic targeting of the kinase activity in cancer cells</i>	233
<i>Heat-activated targeted drug delivery</i>	233
<i>Novel transporters to target photosensitizers to cancer cell nuclei</i>	234
<i>Photodynamic therapy of cancer</i>	234
<i>Radionuclides delivered with receptor targeting technology</i>	235
<i>Targeting ligands specific for cancer cells</i>	235
<i>Targeting abnormal DNA in cancer cells</i>	236
<i>Targeted delivery by tumor-activated prodrug therapy</i>	236
<i>Targeting glutathione S-transferase</i>	238
<i>Targeting tumors by exploiting leaky blood vessels</i>	238
<i>Targeted drug delivery of anticancer agents with controlled activation</i>	239
<i>Targeted delivery of anticancer agents with ReCODE™ technology</i>	239

<i>Transmembrane Carrier Systems</i>	239
<i>Transferrin-oligomers as targeting carriers in anticancer drug delivery</i>	239
<i>Tumor targeting with peptides</i>	240
<i>Ultrasound and microbubbles for targeted anticancer drug delivery</i>	240
<i>Ultrasound for targeted delivery of chemotherapeutics</i>	241
<i>Vitamin B12 and folate for targeting cancer chemotherapy</i>	241
Cell-based drug delivery in cancer.....	243
<i>Red blood cells as vehicles for drug delivery</i>	243
<i>Cells as vehicles for gene delivery</i>	243
Drug delivery in relation to circadian rhythms.....	244
Implants for systemic delivery of anticancer drugs	245
<i>Drug-eluting polymer implants</i>	245
Angiogenesis and drug delivery to tumors	245
Antiangiogenesis strategies	246
<i>Targeting tumor endothelial cells</i>	246
<i>Methods for overcoming limitations of antiangiogenesis approaches</i>	247
Vascular targeting agents	248
<i>Alpha-emitting antibodies for vascular targeting</i>	248
<i>Angiolytic therapy</i>	248
<i>Anti-phosphatidylserine antibodies as VTA</i>	249
<i>Vadimezan</i>	249
<i>Cadherin inhibitors</i>	250
<i>Fosbretabulin tromethamine</i>	250
<i>Drugs to induce clotting in tumor vessels</i>	250
<i>Selective permeation of the anticancer agent into the tumor</i>	250
<i>Targeted delivery of tissue factor</i>	251
<i>Vascular targeting agents versus antiangiogenesis agents</i>	252
<i>ZD6126</i>	252
Delivery of proteins and peptides for cancer therapy	253
<i>CELLECTRA™ electroporation device</i>	253
<i>Emisphere's Eligen™ system</i>	254
<i>Diatos Peptide Vector intra-cellular/intra-nuclear delivery technology</i>	254
<i>Lytic peptides and cancer</i>	254
<i>Modification of proteins and peptides with polymers</i>	255
<i>Peptide-based targeting of cancer biomarkers for drug delivery</i>	255
<i>Peptide-cytokine complexes as vascular targeting agents</i>	256
<i>Peptide-polymer conjugates with radionuclides</i>	256
<i>Transduction of proteins in vivo</i>	256
<i>Tumor targeting by stable toxin (ST) peptides</i>	257
Image-guided personalized drug delivery in cancer	257
A computational approach to integration of drug delivery methods for cancer.....	257

4. Delivery of Biological Therapies for Cancer..... 258

Introduction	258
Antisense therapy	258
Basics of antisense approaches.....	258
Antisense cancer therapy	258
Mechanisms of anticancer effect of antisense oligonucleotides	259
Selected antisense drugs in development for cancer	259
<i>Antisense targeted to ribonucleotide reductase</i>	259
<i>Immune modulatory oligonucleotide</i>	260
Ribozyme therapy	260
Spiegelmers	261
Antisense drug delivery issues.....	261
Strategies to overcome delivery problems of antisense oligonucleotides.....	262
<i>Antisense delivery in microspheres</i>	262
<i>Delivery of antisense using nanoparticles</i>	262
<i>Delivery across the blood-brain barrier</i>	263
<i>Delivery of ribozymes</i>	263
<i>Iontophoretic delivery of oligonucleotides</i>	263
<i>Liposomes-mediated oligonucleotide delivery</i>	264
<i>Neugene™ antisense drugs</i>	264
<i>Oral delivery of oligonucleotides</i>	265
<i>Peptide nucleic acid delivery</i>	265
<i>Receptor-mediated endocytosis</i>	265
<i>Delivery of ribozymes</i>	266
Combination of antisense and electrochemotherapy	266
Aptamers for combined diagnosis and therapeutics of cancer	266
Antisense compounds in clinical trials	267
RNA interference	267
Basics of RNAi	267

Comparison of antisense and RNAi	268
RNAi applications in oncology	268
siRNA-based cancer immunotherapy	269
Delivery of siRNA in cancer	270
<i>Delivery of siRNA by nanoparticles</i>	270
<i>Delivery of siRNA by nanosize liposomes</i>	271
<i>Lipid nanoparticles for delivery of anticancer siRNAs</i>	272
<i>Polymer nanoparticles for targeted delivery of anticancer siRNA</i>	272
Lipophilic siRNA for targeted delivery to solid tumors.....	273
Companies developing cancer therapies based on antisense and RNAi	273
DNA interference	274
Cancer gene therapy	274
Basics of gene therapy	274
Strategies for cancer gene therapy.....	275
Gene transfer techniques as applied to cancer gene therapy.....	276
<i>Viral vectors</i>	276
<i>Nonviral vectors</i>	277
<i>A polymer approach to gene therapy for cancer</i>	277
Direct gene delivery to the tumor	278
<i>Injection into tumor</i>	278
<i>Reversible electroporation</i>	279
Hematopoietic gene transfer	280
<i>Genetic modification of human hematopoietic stem cells</i>	280
Gene-based strategies for immunotherapy of cancer (immunogene therapy).....	281
<i>Cytokine gene therapy</i>	281
Monoclonal antibody gene transfer	284
Transfer and expression of intracellular adhesion-1 molecules	285
Other gene therapy techniques for immunotherapy of cancer	285
<i>Chemokines</i>	285
<i>Engineered viruses as anticancer immunotherapy vectors</i>	286
<i>Fas (Apo-1)</i>	286
<i>IGF (Insulin-Like Growth Factor)</i>	286
<i>Major Histocompatibility Complex (MHC) Class I</i>	286
Inhibition of immunosuppressive function	286
microRNA gene therapy	287
Delivery of toxic genes to tumor cells for eradication (molecular chemotherapy).....	287
<i>Gene-directed enzyme prodrug therapy</i>	287
Combination of gene therapy with radiotherapy.....	288
Multipronged therapy of cancer with microencapsulated cells	289
Correction of genetic defects in cancer cells (mutation compensation)	289
Targeted gene therapy for cancer	290
<i>Transcriptional targeting for cancer gene therapy</i>	290
<i>Targeted epidermal growth factor-mediated DNA delivery</i>	290
<i>Gene-based targeted drug delivery to tumors</i>	290
<i>Targeting gene expression to hypoxic tumor cells</i>	291
<i>Targeting gene expression by progression-elevated gene-3 promoter</i>	291
<i>Targeted delivery of retroviral particles hitchhiking on T cells</i>	292
<i>Targeting tumors with genetically modified T cells</i>	292
<i>Targeting tumors by genetically engineered stem cells</i>	292
<i>Tumor-targeted gene therapy by receptor-mediated endocytosis</i>	293
<i>Targeted site-specific delivery of anticancer genes by nanoparticles</i>	293
<i>Immunolipoplex for delivery of p53 gene</i>	294
<i>Combination of electrogene and electrochemotherapy</i>	294
Virus-mediated oncolysis	294
<i>Targeted cancer treatments based on oncolytic viruses</i>	294
<i>Oncolytic gene therapy</i>	295
<i>Cancer terminator virus</i>	295
<i>Cytokine-induced killer cells for delivery of an oncolytic virus</i>	296
<i>Facilitating oncolysis by targeting innate antiviral response by HDIs</i>	296
<i>Oncolytic HSV</i>	297
<i>Oncolytic adenoviruses</i>	297
<i>Oncolytic Coxsackie virus A21</i>	299
<i>Oncolytic vesicular stomatitis virus</i>	299
<i>Oncolytic measles virus</i>	300
<i>Oncolytic paramyxovirus</i>	300
<i>Oncolytic reovirus</i>	300
<i>Oncolytic vaccinia virus</i>	301
<i>Synthetic oncolytic virus</i>	301
<i>Monitoring of viral-mediated oncolysis by PET</i>	301
<i>Companies developing oncolytic viruses</i>	302
Antiangiogenic therapy for cancer	302

Apoptotic approach to improve cancer gene therapy.....	303
Bacteria as novel anticancer gene vectors	304
Concluding remarks on cancer gene therapy	304
Cancer gene therapy companies	305
Cell therapy for cancer.....	307
Cellular immunotherapy for cancer.....	308
Treatments for cancer by ex vivo mobilization of immune cells	308
Granulocytes as anticancer agents	309
Neutrophil granulocytes in antibody-based immunotherapy of cancer	309
Use of hematopoietic stem cells for targeted cancer therapy	309
Cancer vaccines	310
Cell-based cancer vaccines.....	310
<i>Autologous tumor cell vaccines</i>	310
<i>Vaccines that simultaneously target different cancer antigens</i>	311
<i>Delivery systems for cell-based cancer vaccines</i>	311
<i>Intra-lymph node injections of cancer vaccine antigens</i>	312
Nucleic acid-based cancer vaccines	312
<i>Antiangiogenic DNA cancer vaccine</i>	312
<i>DNA cancer vaccines</i>	313
<i>Methods of delivery of DNA vaccines</i>	313
<i>RNA vaccines</i>	314
Viral vector-based cancer vaccines.....	314
Companies involved in nucleic acid-based vaccines	315
Genetically modified cancer cells vaccines.....	316
<i>GVAX cancer vaccines</i>	316
<i>Genetically modified dendritic cells</i>	317
Multipetide-based cancer vaccines.....	317
5. Delivery strategies according to cancer type and location	319
Introduction	319
Bladder cancer.....	319
Intravesical drug delivery.....	319
Intravesical agents combined with systemic chemotherapy	319
Targeted anticancer therapy for bladder cancer	320
Prodrug EOquin for bladder cancer	320
Antisense treatment of bladder cancer.....	321
Gene therapy for bladder cancer.....	321
Brain tumors.....	321
Methods for evaluation of anticancer drug penetration into brain tumor	322
Innovative methods of drug delivery for glioblastoma multiforme.....	322
Delivery of anticancer drugs across the blood-brain barrier	323
<i>Anticancer agents with increased penetration of BBB</i>	323
<i>BBB disruption</i>	324
<i>Nanoparticle-based targeted delivery of chemotherapy across the BBB</i>	324
<i>Tyrosine kinase inhibitor increases topotecan penetration into CNS</i>	326
Bypassing the BBB by alternative methods of drug delivery.....	326
<i>Intranasal perillyl alcohol</i>	326
<i>Intraarterial chemotherapy</i>	327
Enhancing tumor permeability to chemotherapy	327
Local delivery of chemotherapeutic agents into the tumor	328
<i>Carmustine biodegradable polymer implants</i>	328
<i>Fibrin glue implants containing anticancer drugs</i>	329
<i>Biodegradable microspheres containing 5-FU</i>	329
<i>Magnetically controlled microspheres</i>	329
Convection-enhanced delivery	329
<i>CED for receptor-directed cytotoxin therapy</i>	329
<i>CED of topotecan</i>	330
<i>CED of a modified diphtheria toxin conjugated to transferrin</i>	330
<i>CED of nanoliposomal CPT-11</i>	331
<i>CED for delivery ¹³¹I-chTNT-1/B MAb</i>	331
Anticancer drug formulations for targeted delivery to brain tumors	331
<i>Intravenous delivery of anticancer agents bearing transferrin</i>	331
<i>Liposomes for drug delivery to brain tumors</i>	331
<i>MABs targeted to brain tumors</i>	332
<i>Multiple targeted drugs for brain tumors</i>	332
<i>Nanoparticles for targeted drug delivery in glioblastoma multiforme</i>	333
<i>Targeted antiangiogenic/apoptotic/cytotoxic therapies</i>	334
Introduction of the chemotherapeutic agent into the CSF pathways.....	335
<i>Intraventricular chemotherapy for meningeal cancer</i>	335
<i>Intrathecal chemotherapy</i>	336
Interstitial delivery of dexamethasone for reduction of peritumor edema	336

Combination of chemotherapy with radiotherapy	336
Photodynamic therapy for chemosensitization of brain tumors	337
<i>Nanoparticles for photodynamic therapy of brain tumors</i>	337
Innovative delivery of radiotherapy to brain tumors	337
<i>GliaSite Radiation Therapy System</i>	337
<i>Boron neutron capture therapy for brain tumors</i>	338
Cell therapy for glioblastoma multiforme.....	338
<i>Chimeric antigen receptor T cells</i>	338
<i>Mesenchymal stem cells to deliver treatment for gliomas</i>	338
<i>Stem cell-based therapy targeting EGFR in GBM</i>	339
Gene therapy for glioblastoma multiforme.....	339
<i>Antiangiogenic gene therapy</i>	340
<i>Anticancer drug delivery by genetically engineered MSCs</i>	341
<i>Gene transfer to brain tumor across the BBB by nanobiotechnology</i>	341
<i>Intravenous gene delivery with nanoparticles into brain tumors</i>	341
<i>Ligand-directed delivery of dsRNA molecules targeted to EGFR</i>	341
<i>Neural stem cells for drug/gene delivery to brain tumors</i>	342
<i>Peptides targeted to glial tumor cells</i>	343
<i>RNAi gene therapy of brain cancer</i>	343
<i>Single-chain antibody-targeted adenoviral vectors</i>	343
<i>Targeting normal brain cells with an AAV vector encoding interferon-β</i>	344
<i>Treatment of medulloblastoma by suppressing genes in Shh pathway</i>	344
<i>Virus-mediated oncolytic therapy of glioblastoma multiforme</i>	344
Vaccination for glioblastoma multiforme.....	347
<i>Cell-based vaccines for GBM</i>	347
<i>Peptide vaccines for GBM</i>	347
Oncolytic viral delivery by stem cells for brain metastases of melanoma	348
Breast Cancer	348
Therapies for breast cancer involving innovative methods of drug delivery	349
Injectable biodegradable polymer delivery system for local chemotherapy	349
MammoSite brachytherapy.....	349
Monoclonal antibodies targeted to HER2 receptor.....	350
Breast cancer vaccines	350
<i>HER-2 DNA AutoVacTM vaccine</i>	351
<i>Recombinant adenoviral ErbB-2/neu vaccine</i>	351
<i>Gene vaccine for breast cancer</i>	352
<i>NeuVax</i>	352
Gene therapy for breast cancer.....	353
Antisense therapy for breast cancer	353
Inhibitors of growth factors FGF2 and VEGF for breast cancer	354
Targeted multi-drug delivery approach to breast cancer.....	354
Cancer of the cervix and the uterus	354
Gene therapy for cervical cancer.....	354
Delivery of chemoradiation therapy	355
Cervical cancer vaccines	355
Cancer of the liver	355
Hepatocellular carcinoma	355
Treatment of liver metastases	357
Gastrointestinal cancer	357
Colorectal cancer	357
<i>Oxaliplatin long-circulating liposomes</i>	357
<i>Perifosine</i>	357
<i>Targeted delivery of triple anticancer therapy by local patch</i>	358
Gastrointestinal stromal tumor	358
Vaccines for gastrointestinal cancer.....	358
Hematological malignancies	359
Leukemia.....	359
<i>Clofarabine</i>	360
<i>Ibrutinib</i>	360
<i>Idelalisib for CLL</i>	360
Multiple myeloma.....	360
<i>Monoclonal antibody therapy in multiple myeloma</i>	360
Non-Hodgkin's lymphoma	361
<i>Idelalisib for NHL</i>	361
<i>Pixantrone</i>	361
<i>Rituximab after autologous stem-cell transplantation</i>	362
Malignant melanoma	362
Targeted therapies for melanoma	362
Immunotherapy for malignant melanoma	363
Gene therapy for malignant melanoma	364
Nasopharyngeal carcinoma	366

Synergistic effect of gene therapy with 5-FU	366
Neuroblastoma	366
Genetically modified NSCs for treatment of neuroblastoma	366
Non-small cell lung cancer	367
Aerosol delivery of anticancer agents for lung cancer.....	368
Aerosol gene delivery for lung cancer	369
Complex nanoscale pulmonary delivery of drugs for resistant lung cancer	369
Intratumoral administration of anticancer drugs through a bronchoscope.....	369
Ovarian cancer.....	369
Innovative drug delivery for ovarian cancer.....	370
Intravenous ascorbate for ovarian cancer.....	370
Intraperitoneal delivery	371
Modulation of protein ubiquitination	371
Targeting Notch pathway to overcome resistance to chemotherapy	372
Dendritic cell vaccination for ovarian cancer	372
Gene Therapy for ovarian cancer	372
Pancreatic cancer	373
Delivery of chemotherapy for pancreatic cancer.....	374
<i>Local drug delivery.....</i>	374
<i>Localized drug delivery by iontophoresis</i>	374
<i>Nanoparticle-based delivery of tumor-penetrating peptides</i>	374
<i>Targeted chemotherapy for pancreatic cancer.....</i>	375
<i>Transport properties of pancreatic cancer and gemcitabine delivery</i>	375
Vaccine for pancreatic cancer	375
Gene therapy for pancreatic cancer.....	375
<i>Correction of altered genes</i>	376
<i>Targeted gene therapy</i>	376
<i>Targeting in pancreatic adenocarcinoma with cell surface antigens.....</i>	376
<i>Targeted Expression of BikDD gene.....</i>	377
<i>Viral oncolysis in pancreatic cancer</i>	377
Prostate cancer.....	377
Alpha emitter radium-223 for targeting bone metastases in cancer	378
Brachytherapy for cancer of prostate.....	378
<i>Brachytherapy via paravertebral approach lymph node metastases</i>	379
Capridine-beta.....	379
LHRH for prostate cancer	379
<i>LHRH analogs.....</i>	379
<i>Histrelin implant</i>	380
Immunomodulatory drugs.....	380
MAbs for prostate cancer	380
PACLIMER Microspheres.....	381
PRX302	381
Targeted therapies for prostate cancer	381
<i>Delivery of cisplatin to prostate cancer by nanoparticles</i>	381
<i>Delivery of siRNAs to prostate cancer with aptamer-siRNA chimeras.....</i>	382
<i>Delivery of siRNA for prostate cancer with metastases.....</i>	382
<i>Gold nanoparticles targeted to laminin receptor in prostate cancer.....</i>	382
<i>PSA-activated protoxin that kills prostate cancer.....</i>	382
<i>Targeted delivery of a nanoparticulate platinum prodrug.....</i>	383
<i>Targeting oncogene MDM2 in prostate cancer.....</i>	383
<i>Vascular targeting of prostate cancer</i>	383
Gene therapy for cancer of prostate	384
<i>Experimental studies</i>	384
<i>Nanoparticle-based gene therapy for prostate cancer.....</i>	384
<i>Tumor suppressor gene therapy in prostate cancer</i>	384
<i>Vaccines for prostate cancer.....</i>	385
<i>Clinical trials of gene therapy for prostate cancer.....</i>	385
Viral oncolysis for prostate cancer	386
Combined approaches	387
Combined autovaccination and hyperthermia	387
Thyroid cancer.....	387
6. Cancer drug delivery markets.....	389
Introduction	389
Global markets for drug delivery.....	389
Estimation of cancer drug delivery markets	389
<i>Methods used for market estimation.....</i>	389
<i>Cancer epidemiology</i>	390
<i>Cost of patient care in cancer</i>	392
Market forecasts 2016-2026.....	392
Cancer drug market	392

<i>Market for leukemia</i>	393
<i>Market for lymphoma</i>	393
<i>Markets for brain tumors</i>	394
<i>Market for breast cancer</i>	394
<i>Market for ovarian cancer</i>	394
Geographical distribution of cancer markets	394
Factors affecting future cancer markets	394
Market share according to cancer drug delivery technologies	395
Antiangiogenesis therapies.....	396
Antibody drug conjugates	396
Antineoplastic drug implants for systemic administration	396
Antisense therapy and RNAi	396
Cancer vaccines.....	397
Cell/gene therapy	397
Liposomes for anticancer drugs	397
Monoclonal antibodies	397
Modulators of protein ubiquitination	398
Strategic aspects of cancer drug delivery	398
Unmet needs in cancer drug delivery	398
Future of cancer drug delivery	399
Cancer drug delivery and pharmacogenomics	399
Cancer immunotherapy markets	400
Drug delivery for cancer in the postgenomic era	400
Role of nanobiotechnology in development of cancer drug delivery markets	400
Expansion of cancer drug delivery markets in developing countries	400
Drivers for the development of drug delivery technologies in cancer	400

7. References..... 403

Tables

Table 1-1: Estimated new cases of cancer in the US at most involved organs – 2012	43
Table 1-2: Historical landmarks in drug delivery for cancer	46
Table 2-1: Innovative strategies against cancer.....	49
Table 2-2: A classification of antiangiogenic therapies	52
Table 2-3: Selected antiangiogenic agents in development for cancer.....	58
Table 2-4: Approaches to cancer therapy based on bacteria	60
Table 2-5: Cell therapy technologies used for cancer	68
Table 2-6: Non-nucleic acid cancer vaccines without genetic modification	73
Table 2-7: Monoclonal antibodies for cancer approved by the FDA	85
Table 2-8: Anticancer agents linked to monoclonal antibodies	89
Table 2-9: Monoclonal antibodies in clinical trials for cancer	93
Table 2-10: Antibody drug conjugates in clinical trials for cancer	99
Table 2-11: Third generation boron delivery agents currently under investigation	103
Table 2-12: Cellular pathways as targets for anticancer therapies	111
Table 2-13: Examples of anticancer agents that target mitochondrial membranes.....	112
Table 2-14: Drugs targeting oncogenes	116
Table 2-15: PARP inhibitors for cancer therapy	138
Table 2-16: Cancer therapies based on the P53	143
Table 2-17: Promise of personalized therapy in cancer	148
Table 2-18: Companies developing personalized therapy for cancer	148
Table 3-1: Routes of drug delivery in cancer	155
Table 3-2: Systemic intravenous drug delivery systems for chemotherapy of cancer	155
Table 3-3: Approved oral chemotherapy drugs	157
Table 3-4: Microparticles as therapeutic delivery systems in cancer	170
Table 3-5: Classification of nanobiotechnology approaches to drug delivery in cancer.....	175
Table 3-6: Approved anticancer drugs using nanocarriers	176
Table 3-7: Clinical trials of anticancer drugs using nanocarriers	176
Table 3-8: Marketed preparations for liposome-based anticancer drugs	219
Table 3-9: Clinical trials of liposome-based anticancer drugs	219
Table 3-10: Strategies for drug delivery in cancer.....	223
Table 3-11: Implant systems for delivery of anticancer drugs into tumors.....	225
Table 3-12: Methods of delivery of antiangiogenesis therapies.....	246
Table 3-13: Companies developing vascular targeting agents.....	248
Table 4-1: Mechanisms of anticancer effect of antisense oligonucleotides	259
Table 4-2: Methods of delivery of oligonucleotides for cancer therapy	261
Table 4-3: Antisense oligonucleotides in clinical trials for cancer	267
Table 4-4: Companies developing antisense and RNAi therapies for cancer	273
Table 4-5: Strategies for cancer gene therapy	275
Table 4-6: Enzyme/prodrug combinations employed in suicide gene therapy	288

Table 4-7: Mutation compensation strategies used clinically	289
Table 4-8: Companies developing oncolytic viruses	302
Table 4-9: Companies involved in cancer gene therapy	305
Table 4-10: Cell therapy technologies used for cancer	307
Table 4-11: Companies developing nucleic acids/genetically modified cells-based cancer vaccines	315
Table 5-1: Innovative methods of drug delivery for glioblastoma multiforme	322
Table 5-2: Strategies for gene therapy of malignant brain tumors.....	339
Table 5-3: Clinical trials of oncolytic virotherapy against glioblastoma multiforme.....	346
Table 5-4: Therapies for breast cancer involving innovative methods of drug delivery	349
Table 5-5: Drug delivery for hepatocellular carcinoma	355
Table 5-6: Gene therapy for malignant melanoma	364
Table 5-7: Targeted treatment of non-small cell lung cancer	367
Table 5-8: Clinical trials of gene therapy in ovarian cancer.....	372
Table 5-9: Methods of drug delivery in pancreatic cancer.....	373
Table 5-10: Pharmacological strategies under investigation for cancer of the prostate	377
Table 5-11: Clinical trials of gene therapy for prostate cancer	386
Table 6-1: Worldwide drug delivery market growth 2016 to 2026	389
Table 6-2: Worldwide prevalence of cancer according to type of cancer 2015-2025.....	390
Table 6-3: Estimated number of cancer patients in major markets 2016-2026	391
Table 6-4: Worldwide anticancer drug sales for selected cancers from 2016 to 2026	393
Table 6-5: Geographical distribution of cancer markets 2016-2026	394
Table 6-6: Market values of cancer drug delivery technologies from 2016-2026.....	395

Figures

Figure 1-1: Structure of PD-1 pathway	23
Figure 1-2: An overview of some key steps in tumor angiogenesis.....	38
Figure 2-1: Targeting tumors with light-emitting engineered bacteria.....	62
Figure 2-2: Enhancing tumor-cell visibility to the immune system by viral mimicry	72
Figure 2-3: Schematic role of T helper cells in immune response to cancer	77
Figure 2-4: Antimetabolic anticancer effect of SR9243 by inhibiting Warburg effect.....	142
Figure 3-1: Cyclacel's Penetratin Transport System for delivery of drugs to targets.....	167
Figure 3-2: Micelle for drug delivery in cancer	181
Figure 3-3: Mechanism of action of Targaceutical drugs.....	233
Figure 3-4: VIADUR leuprolide acetate using DUROS implant technology	245
Figure 5-1: A concept of targeted drug delivery to GBM across the BBB.....	325
Figure 6-1: Unmet needs in cancer drug delivery	399